Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Advanced Enzyme Technologies Ltd

₹ 3131.66%
07 Jan – close price
🔗advancedenzymes.com•BSE: 540025•NSE: ADVENZYMES
Market Cap₹ 3,498 Cr.
Current Price₹ 313
High / Low₹ 367
Stock P/E28.6
Book Value₹ 60.0
Dividend Yield1.66 %
ROCE19.9 %
ROE16.9 %
Face Value₹ 2.00
Sales₹ 429 Cr.
OPM22.5 %
Mar Cap₹ 3,498 Cr.

ABOUT

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]

KEY POINTS

Market PositionThe Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally.[1]

Also present in buckets:
Excellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsJv Partnerships AcquisitionsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Anthem Bioscienc655.5079.5836847.930.00173.437.10550.034.7828.501844.5536.40451.51173.4313.3717.350.04
2.Advanced Enzyme312.6028.553497.701.6622.28144.03115.7549.5919.93428.8522.47122.4922.285.2115.490.00
3.Genesis IBRC87.27–113.460.00-0.06-101.640.00-100.0051.620.00–-0.23-0.0613.5949.860.00
4.Vivo Bio Tech32.1117.3570.970.000.87-83.3713.118.899.0450.1242.824.090.870.732.680.58
5.Shree Ganesh Bio0.69171.9127.510.000.01-96.880.77-61.110.6219.57-7.360.160.010.430.410.02
6.Genomic Valley25.1676.867.690.000.00-100.000.09-57.1411.840.6628.790.100.001.968.290.00
–Median: 3 Co.312.654.063497.70.022.287.1115.754.7828.5428.8529.43122.4922.2813.3717.350.0

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
80911018586125839287779777116
Expenses
58677961659459637358706486
Operating Profit
21252225213123291419271430
Other Income
4415154543-1652123
Profit before tax
22252173728123101618251230
Tax %
25%25%26%8%7%9%25%70%29%26%26%26%25%
Net Profit
171915676774183111418922
EPS in Rs
1.491.711.366.046.006.611.560.280.991.221.640.821.99

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
135125139173212222247283273312365351429
Expenses
10791103124162169170183200236260280332
Operating Profit
2834364850537710173761057196
Other Income
1116569799406163
Interest
8543331000010
Depreciation
987889991010111112
Profit before tax
12232544444776987274134121147
Net Profit
10202135363558715556108102122
EPS in Rs
0.911.811.923.103.223.165.196.364.884.979.679.1510.95
Dividend Payout %
11%6%10%13%16%19%12%14%21%20%53%57%–

Compounded Profit Growth

10 Years:18%
5 Years:12%
3 Years:24%
TTM:12%

Compounded Sales Growth

10 Years:11%
5 Years:7%
3 Years:9%
TTM:24%

Return on Equity

10 Years:15%
5 Years:16%
3 Years:17%
Last Year:17%

Stock Price CAGR

10 Years:%
5 Years:-1%
3 Years:4%
1 Year:-9%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
22222222222222222222222222
Reserves
116134152233267297348413458503558607649
Borrowings
59384938451810122232
Other Liabilities
31283725393842534848515776
Total Liabilities
228223261318373376423490530576633689749
Fixed Assets
110106101989897127132132143142156152
Gross Block
109.93105.72170.14106.66113.87121.78160.06174.10183.45203.62212.87237.85–
Accumulated Depreciation
-0.00-0.0068.868.2816.0024.4333.1141.8951.4260.7670.7481.35–
CWIP
2578107107911222131
Investments
282753103120120121184189201256290309
Other Assets
888499108145151165166200220213221257
Total Assets
228223261318373376423490530576633689749

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
183322212335468437505263
Cash from Investing Activity
-7-7-27-55-22-2-25-70-14-42-3-2
Cash from Financing Activity
-11-27434-1-33-19-15-11-12-57-58
Net Cash Flow
-0-1-0-0-002-112-4-84

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
777160656663777066787581
Inventory Days
363389393300234249245240295228268260
Days Payable
907475509066568575546058
Cash Conversion Cycle
350386378316210246265226286252283283
Working Capital Days
2761651085893126109141131155151
ROCE %
10%14%14%18%15%15%21%24%15%15%28%20%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
49.88%49.88%46.52%45.92%43.62%43.50%43.02%42.95%42.92%43.08%43.08%43.08%
FIIs
21.74%21.86%21.89%22.27%22.54%23.01%12.03%12.63%12.57%11.90%23.45%25.41%
DIIs
5.64%5.73%7.58%6.49%6.98%7.56%8.08%8.02%8.17%8.19%8.45%6.41%
Public
22.76%22.54%24.02%25.34%26.88%25.95%36.87%36.40%36.31%36.82%25.00%25.09%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Advanced Enzyme Technologies to Close Trading Window from April 1, 2026

26th March 2026, 11:12 pm

Advanced Enzyme Technologies: Senior VP Marketing & Business Development Resigns

11th March 2026, 10:23 pm

ICRA Assigns Credit Ratings to Advanced Enzyme Technologies Limited's Banking Facilities Worth ₹100 Crore

13th February 2026, 8:18 pm

Advanced Enzyme Technologies Ltd. Announces Special Window for Physical Share Transfer and Dematerialization

10th February 2026, 8:56 pm

Advanced Enzyme Technologies Q3 FY26 Earnings Call: Mixed Performance, U.S. Market Challenges, and R&D Expansion Plans

7th February 2026, 9:59 pm

Published by Other Websites

External media mentions & references

US Tariff Threat Hits Indian Pharma Stocks Hard, Index Down 3%

2nd April 2026, 11:10 am

Maharashtra Village Bags ₹68 Lakh from Soil Sample to Biotech Firm

15th March 2026, 6:07 pm

Advanced Enzyme: Profit Up, Margins Squeezed Amid Green Energy Push

31st January 2026, 1:27 pm

75+ Firms Post Q3 Earnings: IDFC First Bank, GAIL, Sun Pharma Results Due Today

31st January 2026, 8:17 am

Advanced Enzyme EXPLODES 9% After Stunning Q2 Results! Profit & Revenue Skyrocket – What Investors NEED to Know NOW!

12th November 2025, 11:12 am

News Articles

Editorial & research coverage

Advanced Enzyme: Profit Up, Margins Squeezed Amid Green Energy Push
Advanced Enzyme: Profit Up, Margins Squeezed Amid Green Energy Push

31st January 2026, 1:27 pm

Advanced Enzyme EXPLODES 9% After Stunning Q2 Results! Profit & Revenue Skyrocket – What Investors NEED to Know NOW!
Advanced Enzyme EXPLODES 9% After Stunning Q2 Results! Profit & Revenue Skyrocket – What Investors NEED to Know NOW!

12th November 2025, 11:12 am

Advanced Enzyme Q3 Profit Rises 11% Amid Revenue Slip, Margin Pressure
Advanced Enzyme Q3 Profit Rises 11% Amid Revenue Slip, Margin Pressure

Documents

Announcements

Closure of Trading Window
Announcement under Regulation 30 (LODR)-Earnings Call Transcript

17 Nov 2025 - Transcript of the earnings conference call held on November 12, 2025.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

13 Nov 2025 - Audio of Nov 13 conference call on Q2/H1 FY26 unaudited results posted; transcript forthcoming.

Announcement under Regulation 30 (LODR)-Newspaper Publication

13 Nov 2025 - News paper publication with respect to the unaudited financial results for the quarter and half year ended September 30, 2025.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

12 Nov 2025 - Q2 FY26 revenue ₹1,845mn (+26% YoY); PAT ₹447mn (+34%); earnings call Nov 13, 2025.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

Rating update

30 Jan 2025 from crisil

Rating update

28 Dec 2023 from crisil

Rating update

31 Oct 2022 from crisil

Rating update

18 Aug 2021 from crisil

Rating update

16 Oct 2020 from crisil

Rating update

12 Sep 2019 from crisil

Concalls

Nov 2025

TranscriptPPT

Sep 2025

PPT

Aug 2025

TranscriptPPT

May 2025

TranscriptPPT

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPTRecording

Aug 2024

TranscriptPPT

May 2024

TranscriptPPT

Feb 2024

TranscriptPPTRecording

Nov 2023

TranscriptPPT

Aug 2023

TranscriptPPT

May 2023

TranscriptPPT

Feb 2023

TranscriptPPT

Nov 2022

TranscriptPPT

Aug 2022

TranscriptPPT

May 2022

TranscriptPPT

Feb 2022

TranscriptPPT

Nov 2021

TranscriptPPT

Nov 2021

PPT

Oct 2021

PPT

Sep 2021

TranscriptPPT

Aug 2021

PPT

Jun 2021

TranscriptPPT

Mar 2021

Transcript

Feb 2021

TranscriptPPT

Dec 2020

PPT

Nov 2020

TranscriptPPT

Aug 2020

TranscriptPPT

Aug 2020

PPT

Jun 2020

TranscriptPPT

Mar 2020

Transcript

Feb 2020

TranscriptPPT

Feb 2020

PPT

Nov 2019

TranscriptPPT

Nov 2019

PPT

Nov 2019

PPT

Aug 2019

TranscriptPPT

May 2019

TranscriptPPT

Nov 2018

TranscriptPPT

Aug 2018

TranscriptPPT

Jun 2018

TranscriptPPT

May 2018

PPT

May 2018

PPT

May 2018

PPT

Feb 2018

TranscriptPPT

Nov 2017

Transcript

Sep 2017

TranscriptPPT

Jun 2017

PPT

Jun 2017

TranscriptPPT

May 2017

PPT

Mar 2017

PPT

Feb 2017

TranscriptPPT

Nov 2016

TranscriptPPT

Nov 2016

Transcript

Stock Analysis

Description

  1. Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.

Key Growth Triggers

  1. Expansion of product portfolio, particularly in probiotics.
  2. Replicating its successful US B2C model in India with the launch of its 'Wellfa' nutraceutical brand.
  3. Developing biocatalysis for API manufacturers.
  4. Enhancing its baking enzyme offerings in global markets.
  5. Focus on geographical expansion and inorganic opportunities.

Order Book

Currently no data available for Order Book.

Key Red Flags

Currently no data available for Key Red Flags.

Key Dates To Watch

Currently no data available for Key Dates To Watch.

Corporate Announcements

26th Mar 26
Impact Rating: 5
Advanced Enzyme Technologies Limited has informed exchanges that its trading window will be closed from April 1, 2026. This closure continues until 48 hours post announcement of financial results for the quarter and year ended March 31, 2026.
11th Mar 26
Impact Rating: 4
Advanced Enzyme Technologies has informed exchanges about the resignation of Senior Vice President, Mr. Dipak Roda. His cessation from the company will be effective from April 9, 2026.
13th Feb 26
Impact Rating: 5
ICRA Limited has assigned strong credit ratings, including '[ICRA]AA-(Stable)' and '[ICRA]A1+', to Advanced Enzyme Technologies Limited's various banking facilities.
10th Feb 26
Impact Rating: -
No description available.
7th Feb 26
Impact Rating: 7
Advanced Enzyme Technologies posted Q3 FY26 revenue of INR 1,719 million (up 2% YoY) but saw an 11% drop in EBITDA to INR 494 million. The company is focused on R&D and navigating market uncertainties.